Generic drug sponsors may no longer have to wonder why an ANDA had not received a US Food and Drug Administration action if it continues to linger more than two months after its goal date.
Key Takeaways
- The FDA will provide status updates to generic sponsors if complex issues delay an action as part of a new pilot program.
A pilot program potentially launching in November will improve communications in those situations. When a complex regulatory issue forces the...